Correlations between comorbidities, chest x-ray findings, and C-Reactive protein level in patients with COVID-19

Fachri, Muhammad; Hatta, Mochammad; Widowati, Evelin; Akaputra, Risky; Dwiyanti, Ressy; Syukri, Ahmad; Junita, Ade Rifka; Febrianti, Andini; Primaguna, Muhammad Reza

doi:10.1016/j.amsu.2022.103553

Cited by 10 publications

(14 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…COVID-19 can predispose patients to both venous and arterial thromboembolic disease due to the activation of coagulation caused by excessive inflammation, activation of platelets, endothelial dysfunction, and stasis of blood flow related to immobility. Indications of disease severity and the establishment of coagulopathy may vary; these indications include increased D-dimer, thrombocytopenia, elevated D-dimer levels, and prolonged PT and aPTT [ 7 , 8 , [11] , [12] , [13] ].…”

Section: Discussionmentioning

confidence: 99%

“…COC use is associated with a two-to six-fold increase in the risk of VTE. The risk of VTE in COVID-19 can also be exacerbated in pregnancy (the risk increases by four to five times) and in postmenopausal women [ 8 , [17] , [18] , [19] ].…”

Section: Discussionmentioning

confidence: 99%

“…Typical imaging findings include bilateral ground-glass opacities, as well as bilateral multiple lobular and subsegmental areas of consolidation. In severe cases, complications include respiratory failure, septic shock, and multiple organ failure [ [4] , [5] , [6] , [7] , [8] ].…”

Section: Introductionmentioning

confidence: 99%

“…COVID-19 causes patients to enter a hypercoagulable state, but the pathophysiology behind the thrombotic complications observed in this disease is still not well understood. Several mechanisms have been proposed, such as the host immune response, which contributes to vascular endothelial cell injury, inflammation, activation of the coagulation cascade through tissue factor expression, and cessation of fibrinolysis [ [4] , [5] , [6] , [7] , [8] ].…”

Section: Introductionmentioning

confidence: 99%

“…Heparin is also known to have a suppressive effect on the expression of interleukin (IL)-6 and IL-8 in lung epithelial cells, which may help reduce the thrombotic complications associated with the host immune response to COVID-19. LMWH (fondaparinux) is an indirect factor Xa inhibitor, but LMWH (fondaparinux) does not inhibit thrombin at all, which is why LMWH (fondaparinux) is better for preventing heparin-induced thrombocytopenia [ 4 , 5 , [7] , [8] , [9] ]. The aim of this study was to compare the effectiveness of unfractionated heparin (UFH) and LMWH (fondaparinux) in hospitalised COVID-19 patients with hypercoagulable complications.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study

Fachri

Hatta

Tarigan

et al. 2022

Annals of Medicine &Amp; Surgery

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study

Fachri

Hatta

Tarigan

et al. 2022

Annals of Medicine &Amp; Surgery

Self Cite

View full text Add to dashboard Cite

Analysis of natural resistance-associated macrophage protein-1 (NRAMP-1) level based on death, comorbidities and severity of COVID-19 patients: a cross-sectional study

Dwiyanti,

Muthaher,

Achmad

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Background: An accurate diagnosis of COVID-19 is essential for pandemic control and for establishing adequate therapeutic strategies to reduce morbidity and mortality. COVID-19 infection replicates in macrophage cells and affects the immune system. Natural resistance-associated macrophage protein-1 (NRAMP-1) carries cation ions, such as Fe2+, Zn2+ and Mn2+, and plays an essential role in the immune system to infection with micro-organisms. In addition, the function of NRAMP-1 is to limit the replication of pathogens by changing the phagosomal environment. Levels of NRAMP-1 protein are based on death, comorbidities and clinical symptoms of COVID-19 patients and it is possible for the soluble protein NRAMP-1 level to be used as an additional biomarker for forensic and medicolegal related COVID-19 cases and prosecutions from patients and families. Methods: Determination of NRAMP-1 protein levels using the enzyme link-immunosorbent assay technique in death, had comorbidities and severity of clinical symptoms of COVID-19 patients. Results: Of the 62 patients who received treatment, 10 patients died with an average NRAMP-1 level of 650 ng/ml and 52 patients who survive with an average NRAMP-1 level of 1065.26 ng/ml. The results of the study also found that 34 patients had comorbidities with an average NRAMP-1 level of 838.82 ng/ml and 28 patients without comorbidities with an average NRAMP-1 level of 1191.92 ng/ml. Based on the severity of clinical symptoms in survive patients, 10 patients with mild were found with an average NRAMP-1 level of 984.31 ng/ml, with moderate in 31 patients with an average NRAMP-1 level of 1104.71 ng/ml and severe in 11 patients with an average NRAMP-1 level of 1027.71 ng/ml. Conclusions: NRAMP-1 protein levels were significantly lower in COVID-19 patients who died and had comorbidities.

show abstract

Eosinophil values in exacerbation and stable chronic obstructive pulmonary disease and its relationship to maintenance therapy in stable chronic obstructive pulmonary disease patients

Fachri,

Hatta,

Lestari

et al. 2023

Annals of Medicine &Amp; Surgery

Self Cite

View full text Add to dashboard Cite

Background: Chronic obstructive pulmonary disease (COPD) is characterised by persistent and progressive airflow limitations. The study aimed to determine the relationship between eosinophil values in patients with stable and exacerbated COPD, and the relationship of eosinophil values with two drug regimens used as maintenance therapy in stable COPD. Materials and methods: This cross-sectional study and the variables used in this study were eosinophil counts in stable and exacerbated COPD patients. Results: Eighty-three patients with stable and exacerbated COPD were included. Stable COPD (63.9%) was predominant, with the highest degree of symptoms in group A 18 patients (34%) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2; 35 patients (66%). The degree of COPD exacerbation was dominated by Type II COPD 15 patients (50%). Eosinophil counts in patients with stable COPD were less than 100 cells/mm3 37 patients (44.6%), while in patients with COPD exacerbation, it was greater than 100 cells/mm3 with a total of 30 patients (36.1%). Long acting muscarinic antagonist class of drugs was the most used treatment as maintenance therapy in stable COPD 34 patients (64.2%). Conclusion: The eosinophil counts in patients with COPD exacerbation were significantly higher than those in patients with stable COPD. The provision of maintenance therapy in the long acting β-2 agonist + inhaled glucocorticosteroid group of stable COPD patients was generally provided to COPD patients with eosinophil values greater than 100 cells/mm3, and the provision of long-term maintenance therapy in stable COPD patients was generally given to COPD patients with eosinophil values less than 100 cells/mm3.

show abstract

Correlations between comorbidities, chest x-ray findings, and C-Reactive protein level in patients with COVID-19

Cited by 10 publications

References 32 publications

Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study

Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study

Analysis of natural resistance-associated macrophage protein-1 (NRAMP-1) level based on death, comorbidities and severity of COVID-19 patients: a cross-sectional study

Eosinophil values in exacerbation and stable chronic obstructive pulmonary disease and its relationship to maintenance therapy in stable chronic obstructive pulmonary disease patients

Contact Info

Product

Resources

About